Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antivirals
Description
The coronavirus disease 2019 (COVID-19) pandemic, driven by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has highlighted the urgent need for effective therapeutics, particularly as limitations of existing antiviral treatments persist
